Compare Palantir Technologies Inc (PLTR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Palantir Technologies Inc trades at $195.7 (market cap $482.94B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Palantir Technologies Inc is far larger — about 65.7× Spyre Therapeutics Inc. Common Stock's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 79 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PLTR | SYRE | |
|---|---|---|
Market Cap | $482.94B | $7.35B |
Volume | 24,103,301 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $209.05 | $108.92 |
52-Week Low | $107.27 | $22.18 |
Typical Hold Time | 79 Days | 0 Days |
Enterprise Value | $473.74B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $208.64, down slightly by 0.17% on the day, but maintains strong bullish momentum with the stock near recent highs. The company continues to demonstrate exceptional financial performance with 56.2% revenue growth in 2025, net income margin of 49%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure highlights ongoing business expansion. Technical indicators show strong bullish sentiment with the stock trading above key support levels.
Palantir presents a compelling growth story with accelerating revenue and profitability, though premium valuations require continued execution. The stock faces risks from high expectations and potential growth deceleration, but strong institutional support and AI leadership provide upside potential. Current analyst consensus suggests moderate upside from current levels with 54% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
